Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 20.9%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 3,592,118 shares, an increase of 20.9% from the February 26th total of 2,971,195 shares. Approximately 19.9% of the company’s shares are short sold. Based on an average trading volume of 713,792 shares, the short-interest ratio is currently 5.0 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on KPTI shares. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an “overweight” rating for the company. HC Wainwright decreased their price target on shares of Karyopharm Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $8.00 target price (down from $12.00) on shares of Karyopharm Therapeutics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.29.

Institutional Investors Weigh In On Karyopharm Therapeutics

Large investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth $74,000. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. Tudor Investment Corp ET AL purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at about $95,000. XTX Topco Ltd acquired a new stake in shares of Karyopharm Therapeutics during the second quarter valued at about $56,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at about $135,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Performance

KPTI stock opened at $5.82 on Thursday. The firm has a market cap of $106.74 million, a P/E ratio of -0.35 and a beta of 0.40. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.99. The stock has a 50-day simple moving average of $7.69 and a 200-day simple moving average of $6.81.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The company had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. On average, equities research analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.